dm+d

Unassigned

New Medicines

MydicarHeart failure, chronic, advanced

Information

Mydicar
New molecular entity
Celladon
Celladon

Development and Regulatory status

Suspended
Suspended
Suspended
Apr 15: Following disappointing results from the CUPID-2b trial, further development is unlikely [1].

Category

Genetically targeted enzyme replacement therapy intended to restore levels of SERCA2a, a regulator of calcium cycling and contractility
Prevalence of asymptomatic ventricular dysfunction is approximately 4%. Prevalence of heart failure is between 2-4% in the general population, increasing significantly with age to between 10-20% in the over-75s [6].
Heart failure, chronic, advanced
Intracoronary